UroGen Pharma

UroGen Pharma is a biotechnology company focused on developing and commercializing innovative solutions for urothelial and specialty cancers. Driven by a commitment to putting patients first, UroGen has created a proprietary sustained-release, hydrogel-based platform technology called RTGel that has the potential to improve therapeutic profiles of existing drugs. This technology allows for longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.

UroGen's first commercial product, Jelmyto, is a mitomycin-containing reverse thermal gel indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). UroGen is also developing UGN-102, an investigational treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), which has shown promising results in clinical trials. With a focus on research and development, UroGen is dedicated to exploring and developing novel solutions that address real patient needs and the current burdens of treatment, ultimately transforming the paradigm in uro-oncology.

UroGen Pharma offers a variety of work arrangements, including hybrid positions that allow for a combination of in-office and remote work, as well as fully remote roles for some positions. Specific locations for hybrid work are noted in each job posting, while fully remote positions indicate the specific location is remote. The company also has a corporate headquarters in Princeton, NJ, and a research and development site in Ra'anana, Israel.

UroGen Pharma is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, believing that patients deserve better treatment options. They strive to fundamentally change the way patients are treated for urologic cancers by transforming the paradigm in uro-oncology with their treatments, all while maintaining a commitment to ethical business practices and fostering a diverse and inclusive workplace.

UroGen Pharma promotes a culture that prioritizes patients and fosters a collaborative and innovative environment. They value diversity and inclusion, believing that a spectrum of backgrounds and perspectives makes them stronger. Open dialogue and transparency are encouraged through an open-door policy and internal organizations like the Culture Council. Agility and adaptability are essential, as employees are empowered to wear multiple hats and find solutions when challenges arise. The company values boldness, inventiveness, and staying connected, emphasizing a team-oriented approach to achieving their mission of transforming the paradigm in uro-oncology.

UroGen Pharma values diversity and inclusion, believing that cancer doesn't discriminate and that a diverse team strengthens the company. They celebrate differences in race, ethnicity, gender identity, sexual orientation, age, religion, and disability, striving to include perspectives from all walks of life. They also foster an open dialogue environment through transparent policies and internal organizations, like the UroGen Culture Council, which promotes cross-departmental connection and collaboration.